United Therapeutics

United Therapeutics

Yahoo Finance • 5 days ago

United Therapeutics' Q2 Tyvaso Miss Reflects Competition; IPF Outreach Set to Expand, Morgan Stanley Says

United Therapeutics' (UTHR) Q2 miss for Tyvaso reflected pressure from rising competition, though th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 16 days ago

PINK vs. XLV: How Do These Two Health Care ETFs Match Up?

Investors choosing between Simplify Health Care ETF (NYSEMKT:PINK) and State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) may weigh the SPDR fund's significantly lower costs against the Simplify fund's active management and char... Full story

Yahoo Finance • 18 days ago

United Therapeutics Appoints Victor Dzau To Board Of Directors

(RTTNews) - United Therapeutics Corporation (UTHR), announced on Thursday the appointment of Victor Dzau to its Board, effective immediately. Dzau recently completed a 12-year term as President at the National Academy of Medicine and curr... Full story

Yahoo Finance • 20 days ago

Liquidia jumps as judge criticizes United Therapeutics in patent dispute

[Judge Gavel Beside Open Law Book With Turning Pages] jittawit.21/iStock via Getty Images Liquidia Corp. (LQDA [https://seekingalpha.com/symbol/LQDA]) rose 8% after a judge in a long-standing patent dispute with United Therapeutics (UTHR... Full story

Yahoo Finance • 21 days ago

PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?

Investors comparing these two funds are really choosing between two different philosophies. The iShares Global Healthcare ETF (NYSEMKT:IXJ) is a low-cost, diversified way to own the global healthcare sector. The Simplify Health Care ETF (N... Full story

Yahoo Finance • 28 days ago

Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1

Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1 Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at Gil... Full story

Yahoo Finance • 28 days ago

Here’s Laughing Water Capital’s Updates on Liquidia Corp. (LQDA)

Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment i... Full story

Yahoo Finance • 29 days ago

Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?

Liquidia Corporation LQDA is banking on lead drug's Yutrepia's ability to sustain its strong commercial momentum despite intense competition in the pulmonary arterial hypertension (PAH) market. The drug is an inhaled dry-powder version of... Full story

Yahoo Finance • last month

Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let's have a look at AbbVie (NYSE:ABBV) and its p... Full story

Yahoo Finance • last month

United Therapeutics buys Thymmune Therapeutics

* United Therapeutics (UTHR [https://seekingalpha.com/symbol/UTHR]) said it acquired [https://seekingalpha.com/pr/20571167-united-therapeutics-corporation-acquires-thymmune-therapeutics] privately held preclinical biotech Thymmune Therap... Full story

Yahoo Finance • last month

Big Pharma Has a Case of Merger Mania

In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Tyler Crowe, Matt Frankel, and Lou Whiteman take a dive into what’s driving the merger-and-acquisition frenzy, including: Big pharma is using big wallets for M... Full story

Yahoo Finance • last month

Is MannKind Corporation (MNKD) A Good Stock To Buy Now?

Is MNKD a good stock to buy? We came across a bullish thesis on MannKind Corporation on BioEquity Watch's Substack. In this article, we will summarize the bulls' thesis on MNKD. MannKind Corporation's share was trading at $3.8400 as of Jun... Full story

Yahoo Finance • 2 months ago

A Look At United Therapeutics (UTHR) Valuation After Strong Long Term Shareholder Returns

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. United Therapeutics overview United Therapeutics (UTHR) has drawn... Full story

Yahoo Finance • 2 months ago

Healthcare Giants or Medical Innovators? XLV and PINK Are Built for Different Investors.

The State Street Health Care Select Sector SPDR ETF(NYSEMKT:XLV) provides low-cost, passive exposure to established healthcare giants, while the Simplify Health Care ETF (NYSEMKT:PINK) offers an active strategy targeting medical breakthrou... Full story

Yahoo Finance • 2 months ago

Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics

[Supreme Court of the United States. Washington DC, USA.] Mindaugas Dulinskas The Supreme Court unanimously sided with generic drugmaker Hikma (HKMPF [https://seekingalpha.com/symbol/HKMPF]) and against Amarin Corp. (AMRN [https://seeking... Full story

Yahoo Finance • 2 months ago

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year

Key Points Krensavage bought 241,245 Ultragenyx Pharmaceutical shares last quarter. The quarter-end position value increased by $4.75 million, reflecting both trading and share price changes. The trade represented a roughly 2% increase in... Full story

Yahoo Finance • 2 months ago

United Therapeutics Corporation (UTHR): Renaissance Technologies Likes This Biotech Stock

We just covered the 12 Best Stocks to Invest In According to Jim Simons’ Renaissance Technologies and United Therapeutics Corporation (NASDAQ:UTHR) ranks 1st on this list. United Therapeutics Corporation (NASDAQ:UTHR) is a long-term holdi... Full story

Yahoo Finance • 3 months ago

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story

Yahoo Finance • 3 months ago

5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call

United Therapeutics' first quarter results fell below Wall Street's revenue and earnings expectations, but the market responded favorably. Management attributed the shortfall mainly to seasonality and operational disruptions, including sev... Full story

Yahoo Finance • 3 months ago

Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wells Fargo upgraded United Therapeutic... Full story